Sign In
Buy EVO
Evotec SE Earnings Calls
| Release date | Aug 13, 2026 |
| EPS estimate | -$0.0470 |
| EPS actual | - |
| Revenue estimate | 177.244M |
| Revenue actual | - |
| Expected change | +/- 4.54% |
| Release date | May 06, 2026 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.464 |
| EPS Surprise | -209.49% |
| Revenue estimate | 204.391M |
| Revenue actual | 213.621M |
| Revenue Surprise | 4.52% |
| Release date | Apr 08, 2026 |
| EPS estimate | $0.211 |
| EPS actual | $0.0549 |
| EPS Surprise | -73.96% |
| Revenue estimate | 328.778M |
| Revenue actual | 347.641M |
| Revenue Surprise | 5.74% |
| Release date | Nov 05, 2025 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.142 |
| EPS Surprise | -1.44% |
| Revenue estimate | 239.92M |
| Revenue actual | 191.953M |
| Revenue Surprise | -19.99% |
Last 4 Quarters for Evotec SE
Below you can see how EVO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 05, 2025 |
| Price on release | $3.35 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.142 |
| EPS surprise | -1.44% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $4.06 |
| Oct 31, 2025 | $4.07 |
| Nov 03, 2025 | $4.02 |
| Nov 04, 2025 | $3.97 |
| Nov 05, 2025 | $3.35 |
| Nov 06, 2025 | $3.31 |
| Nov 07, 2025 | $3.08 |
| Nov 10, 2025 | $2.99 |
| Nov 11, 2025 | $2.97 |
| 4 days before | -17.61% |
| 4 days after | -11.21% |
| On release day | -1.20% |
| Change in period | -26.85% |
| Release date | Apr 08, 2026 |
| Price on release | $2.69 |
| EPS estimate | $0.211 |
| EPS actual | $0.0549 |
| EPS surprise | -73.96% |
| Date | Price |
|---|---|
| Apr 01, 2026 | $2.54 |
| Apr 02, 2026 | $2.59 |
| Apr 06, 2026 | $2.62 |
| Apr 07, 2026 | $2.58 |
| Apr 08, 2026 | $2.69 |
| Apr 09, 2026 | $2.62 |
| Apr 10, 2026 | $2.63 |
| Apr 13, 2026 | $2.78 |
| Apr 14, 2026 | $3.12 |
| 4 days before | 5.91% |
| 4 days after | 15.99% |
| On release day | -2.60% |
| Change in period | 22.83% |
| Release date | May 06, 2026 |
| Price on release | $3.24 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.464 |
| EPS surprise | -209.49% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $3.11 |
| May 01, 2026 | $3.09 |
| May 04, 2026 | $3.12 |
| May 05, 2026 | $3.20 |
| May 06, 2026 | $3.24 |
| May 07, 2026 | $3.05 |
| May 08, 2026 | $3.07 |
| May 11, 2026 | $3.06 |
| May 12, 2026 | $3.00 |
| 4 days before | 4.18% |
| 4 days after | -7.41% |
| On release day | -5.86% |
| Change in period | -3.54% |
| Release date | Aug 13, 2026 |
| Price on release | - |
| EPS estimate | -$0.0470 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 27, 2026 | $1.92 |
| Jul 28, 2026 | $1.96 |
| Jul 29, 2026 | $1.93 |
| Jul 30, 2026 | $1.93 |
| Jul 31, 2026 | $1.91 |
Evotec SE Earnings Call Transcript Summary of Q1 2026
Evotec reported Q1 2026 revenues of EUR 156.6m and adjusted EBITDA of negative EUR 21.9m. Management reiterated full-year 2026 guidance (EUR 700m–789m reported / EUR 730m–810m at constant FX for revenues; adjusted EBITDA EUR 0m–40m reported / EUR 10m–15m at constant FX) and expects a stronger second half driven by market recovery in discovery & preclinical development (D&PD), contributions from strategic partnerships/milestones and Horizon restructuring savings. The Horizon transformation—focused on operational excellence, science leadership and commercial execution—moved from planning into implementation (works council consultations in Europe, Framingham exit in the U.S.), with EUR 75m of reorganization provisions recorded in Q1 and targeted structural run-rate savings of ~EUR 75m by end-2027 (20–30% to materialize in 2026). Leadership was strengthened with new CFO Claire Hinshelwood and new COO Ingrid Muller. Commercial leading indicators (proposal activity, lower change orders, faster proposal turnaround) showed early improvement, and the company highlighted recent partnership milestones (Gates Foundation grants, Almirall program) validating its AI-enabled D&PD platforms. Liquidity at quarter-end was EUR 444.8m (net cash position) and excludes expected gross proceeds of ~USD 100m from Gilead’s Tubulis acquisition anticipated in Q2 2026. Management emphasized the quarter’s year-on-year decline reflected a nonrecurring Q1 2025 Sandoz license and FX headwinds rather than a change in long-term strategy, and stated a strategic evaluation of portfolio/corporate structure is underway (no predetermined outcome).
